Skip to content
tepoxalin

Structure via PubChem · Public domain (PubChem)

EntityQ7701370· pop 6· linked from 282 articles

Also known as RWJ 20485, 5-(p-Chlorophenyl)-1-(p-methoxyphenyl)-N-methylpyrazole-3-propionohydroxamic acid, ORF-20485, ORF 20485

Tepoxalin, sold under the brand name Zubrin among others, is a non-steroidal anti-flammatory drug (NSAIDs) generally used in veterinary medicine to reduce swelling in animals with osteoarthritis. In rare circumstances, tepoxalin can also be used in human pharmacology to relieve pain caused by musculoskeletal conditions such as arthritis and hip dysplasia.

Chemical data

Formula
C20H20ClN3O3
Molecular weight
385.8 g/mol
IUPAC name
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-N-hydroxy-N-methylpropanamide
SMILES
CN(C(=O)CCC1=NN(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)OC)O
InChIKey
XYKWNRUXCOIMFZ-UHFFFAOYSA-N
XLogP
3.4
Polar surface area
67.6 Ų
H-bond donors
1
H-bond acceptors
4
Formal charge
0

via PubChem

Drug data · ChEMBL

Max clinical phase
Phase 2
Molecule type
Small molecule

via ChEMBL · EBI

Wikidata facts

Mass
385.119
Show 6 more facts
chemical formula
C₂₀H₂₀ClN₃O₃
canonical SMILES
CN(C(=O)CCC1=NN(C(=C1)C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)OC)O
World Health Organisation international non-proprietary name
tepoxalin
subject has role
immunosuppressive drug
medical condition treated
osteoarthritis
Commons category
Tepoxalin
Sources (4)

via Wikidata · CC0

~7 min read

Encyclopedic overview

7 sections
Contents
  • Approval
  • Pharmacology and biochemistry
  • Canine and feline uses
  • Equine use
  • Adverse effects
  • Synthesis
  • References

Tepoxalin, sold under the brand name Zubrin among others, is a non-steroidal anti-flammatory drug (NSAIDs) generally used in veterinary medicine to reduce swelling in animals with osteoarthritis. In rare circumstances, tepoxalin can also be used in human pharmacology to relieve pain caused by musculoskeletal conditions such as arthritis and hip dysplasia.

In 1997, tepoxalin was patented for veterinary use, replacing isoxazole for treating inflammation. In 2017, the drug was withdrawn from the American market and can no longer be administered in the United States.

Excerpted from Wikipedia’s “tepoxalin” article, available under the CC BY-SA 4.0 licence.

Available in 5 languages

via Wikidata sitelinks · CC0